Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G9OC
|
|||
| Former ID |
DPR000173
|
|||
| Drug Name |
BMS-PCSK9
|
|||
| Drug Type |
Antisense drug
|
|||
| Indication | Coronary artery disease [ICD-11: BA80; ICD-10: I25.1, I25.4] | Preclinical | [1] | |
| Company |
ISIS Pharm; Bristol-Myers Squibb
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | PCSK9 messenger RNA (PCSK9 mRNA) | Target Info | . | [1] |
| WikiPathways | PCSK9-mediated LDLR degradation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.